These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22865774)

  • 1. A conditional error function approach for subgroup selection in adaptive clinical trials.
    Friede T; Parsons N; Stallard N
    Stat Med; 2012 Dec; 31(30):4309-20. PubMed ID: 22865774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-to-event analysis with treatment arm selection at interim.
    Di Scala L; Glimm E
    Stat Med; 2011 Nov; 30(26):3067-81. PubMed ID: 21898523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision oncology: A new era of cancer clinical trials.
    Renfro LA; An MW; Mandrekar SJ
    Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive designs for confirmatory clinical trials with subgroup selection.
    Stallard N; Hamborg T; Parsons N; Friede T
    J Biopharm Stat; 2014; 24(1):168-87. PubMed ID: 24392984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusted significance levels for subgroup analyses in clinical trials.
    Spiessens B; Debois M
    Contemp Clin Trials; 2010 Nov; 31(6):647-56. PubMed ID: 20832503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASIED: a Bayesian adaptive subgroup-identification enrichment design.
    Xu Y; Constantine F; Yuan Y; Pritchett YL
    J Biopharm Stat; 2020 Jul; 30(4):623-638. PubMed ID: 31782938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim.
    Posch M; Maurer W; Bretz F
    Pharm Stat; 2011; 10(2):96-104. PubMed ID: 22328314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of the optimal personalized treatment from multiple treatments with multivariate outcome measures.
    Siriwardhana C; Datta S; Kulasekera KB
    J Biopharm Stat; 2020 May; 30(3):462-480. PubMed ID: 31691633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of the interim analysis in adaptive enrichment designs.
    Benner L; Kieser M
    J Biopharm Stat; 2018; 28(4):622-632. PubMed ID: 29064745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapy: a potential oversight in trial protocol.
    Moorthy T
    Lancet Oncol; 2018 Sep; 19(9):e439. PubMed ID: 30191846
    [No Abstract]   [Full Text] [Related]  

  • 14. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive graph-based multiple testing procedures.
    Klinglmueller F; Posch M; Koenig F
    Pharm Stat; 2014; 13(6):345-56. PubMed ID: 25319733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familywise error control in multi-armed response-adaptive trials.
    Robertson DS; Wason JMS
    Biometrics; 2019 Sep; 75(3):885-894. PubMed ID: 30714095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup.
    Sugitani T; Posch M; Bretz F; Koenig F
    Stat Med; 2018 Oct; 37(24):3387-3402. PubMed ID: 29945304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.
    Johnston SE; Lipkovich I; Dmitrienko A; Zhao YD
    Pharm Stat; 2022 Sep; 21(5):1090-1108. PubMed ID: 35322520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.